Evidence map›Paper›PMID 41951457›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2026

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

E Felip, C I Rojas, M Schenker, D M Kowalski, I A Casarini, T Csöszi, M A N Şendur, J Martins, A Calles Blanco, C-C Wang and 9 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

E FelipVall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: efelip@vhio.net.
C I RojasBradfordhill-Clinical Area, Santiago, Chile.
M SchenkerMedical Oncology, Sfântul Nectarie Oncology Center, Craiova, Romania.
D M KowalskiDepartment of Lung Cancer and Thoracic Tumours, Marie Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
I A CasariniHospital Houssay, Mar del Plata, Buenos Aires, Argentina.
T CsösziHetényi Géza Hospital, Oncology Center of Jász-Nagykun-Szolnok County, Szolnok, Hungary.
M A N ŞendurAnkara Yıldırım Beyazıt University and Ankara Bilkent City Hospital, Ankara, Turkey.
J MartinsJoinville Institute of Hematology and Oncology, Joinville, Brazil.
A Calles BlancoGregorio Marañon University General Hospital, Madrid, Spain.
C-C WangChang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan.
M WangBeijing Peking Union Medical College Hospital, Beijing, China.
R A L Ramirez FallasPrivate Practice, Guatemala City, Guatemala.
H YoshiokaKansai Medical University Hospital, Osaka, Japan.
S NairMid Florida Hematology and Oncology Center, Orange City, USA.
X SongShanxi Cancer Hospital, Shanxi, China.
X DengMerck & Co., Inc., Rahway, USA.
M LalaMerck & Co., Inc., Rahway, USA.
R EirasMerck & Co., Inc., Rahway, USA.
T TakahashiShizuoka Cancer Center, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41951457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.